RemeGen's disitamab vedotin with Junshi Pharma's Loqtorzi beat standard chemotherapy in first-line HER2-expressing metastatic urothelial cancer.
17h
New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...
Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...
Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick ...
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated ...
When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
Scientists have developed compounds that selectively block a crucial interaction between RAS and the enzyme PI3K, a driver of tumor growth. Scientists from the Francis Crick Institute and Vividion The ...
Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...
New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback